Is Merck's Stock Still a Good Buy at $150?
The healthcare stock has surged nearly 40% this year.
Merck's stock has seen a significant 40% increase in 2026, outperforming the broader market's 9% growth. The company's shares recently reached a record high of nearly $157, but have since settled around $150. Investors are wondering if this healthcare giant remains a good buy at this price. Key concern has been the expiration of patents for Merck's blockbuster cancer drug Keytruda in 2028, raising questions about future growth.
However, the company recently launched a subcutaneous version, Keytruda Qlex, which has exceeded expectations with $830 million in revenue in Q3, including $830 million from Qlex. This gives investors hope that Keytruda's earnings won't plummet as generics enter the market. Yet, Merck still generates almost half of its revenue from Keytruda, so revenue drops when generics hit the market is inevitable.
The stock's forward P/E multiple of 16, based on analysts' earnings expectations, is lower than the S&P 500's average of 19, indicating a slight discount. But this isn't a substantial bargain. The stock has surged this year, but The Motley Fool advises waiting before purchasing, as it may have more downside risk than upside. Analysts' top 10 stock picks, available with a Stock Advisor subscription, have delivered a market-beating 823% return since Nov. 16, 2026.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.